Summit Therapeutics (SMMT) EPS (Weighted Average and Diluted) (2022 - 2025)
Summit Therapeutics (SMMT) has disclosed EPS (Weighted Average and Diluted) for 4 consecutive years, with -$0.28 as the latest value for Q4 2025.
- For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) fell 211.11% year-over-year to -$0.28, compared with a TTM value of -$1.44 through Dec 2025, down 364.52%, and an annual FY2025 reading of -$1.44, down 364.52% over the prior year.
- EPS (Weighted Average and Diluted) was -$0.28 for Q4 2025 at Summit Therapeutics, up from -$0.31 in the prior quarter.
- Across five years, EPS (Weighted Average and Diluted) topped out at $0.4 in Q2 2023 and bottomed at -$1.43 in Q1 2023.
- Average EPS (Weighted Average and Diluted) over 4 years is -$0.21, with a median of -$0.09 recorded in 2024.
- Peak annual rise in EPS (Weighted Average and Diluted) hit 95.8% in 2024, while the deepest fall reached 800.0% in 2024.
- Year by year, EPS (Weighted Average and Diluted) stood at -$0.04 in 2022, then skyrocketed by 75.0% to -$0.01 in 2023, then crashed by 800.0% to -$0.09 in 2024, then tumbled by 211.11% to -$0.28 in 2025.
- Business Quant data shows EPS (Weighted Average and Diluted) for SMMT at -$0.28 in Q4 2025, -$0.31 in Q3 2025, and -$0.76 in Q2 2025.